AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 29248319 — intervention group
Group type: EXPERIMENTAL
Intervention: Gemcitabine and Cisplatin (GC) plus Ipilimumab
Number of subjects: 36
Study 29248621 — intervention group
Group type: EXPERIMENTAL
Intervention: Childhood asthma
Number of subjects: 4915
Study 29248621 — intervention group
Group type: EXPERIMENTAL
Intervention: ACO (Asthma-COPD Overlap)
Number of subjects: 4915
Study 29248621 — intervention group
Group type: EXPERIMENTAL
Intervention: Childhood pneumonia
Number of subjects: 4915
Study 29248621 — intervention group
Group type: COMPARATOR
Intervention: No early-life respiratory diseases (Control)
Number of subjects: 4915
Study 29248659 — intervention group
Group type: EXPERIMENTAL
Intervention: Ferumoxytol-Enhanced Magnetic Resonance Angiography
Number of subjects: 0
Study 29248669 — intervention group
Group type: EXPERIMENTAL
Intervention: Haemopoietic stem-cell transplantation (HSCT) after myeloablation
Number of subjects: 23
Study 29248894 — intervention group
Group type: EXPERIMENTAL
Intervention: Standardised frankincense extract (SFE)
Number of subjects: 38
Study 29249180 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal rotigotine
Number of subjects: 378
Study 29249202 — intervention group
Group type: EXPERIMENTAL
Intervention: Direct-acting antiviral (DAA) treatment
Number of subjects: 156811
Study 29249202 — intervention group
Group type: EXPERIMENTAL
Intervention: Model projections with 30% treatment coverage (TC) rate
Number of subjects: 156811
Study 29249202 — intervention group
Group type: EXPERIMENTAL
Intervention: Model projections with increased TC rate in HR MSM to 50%
Number of subjects: 156811
Study 29249202 — intervention group
Group type: EXPERIMENTAL
Intervention: Model projections with increased TC rate in HR MSM to 70%
Number of subjects: 156811
Study 29249202 — intervention group
Group type: EXPERIMENTAL
Intervention: Model projections with 30% TC rate
Number of subjects: 156811
Study 29250012 — intervention group
Group type: EXPERIMENTAL
Intervention: Body-Affective Mindfulness Intervention
Number of subjects: 0
Study 29250012 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 29250743 — intervention group
Group type: EXPERIMENTAL
Intervention: Early tapering of immunosuppressive agents
Number of subjects: 63
Study 29250743 — intervention group
Group type: COMPARATOR
Intervention: Routine tapering of immunosuppressive agents
Number of subjects: 63
Study 29251207 — intervention group
Group type: EXPERIMENTAL
Intervention: Fast-track EVAR protocol
Number of subjects: 250
Study 29251556 — intervention group
Group type: EXPERIMENTAL
Intervention: Ambrisentan and tadalafil combination therapy
Number of subjects: 21
Study 29251709 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronic Critical Illness (CCI) patients
Number of subjects: 145
Study 29251709 — intervention group
Group type: COMPARATOR
Intervention: RAP patients
Number of subjects: 145
Study 29251709 — intervention group
Group type: EXPERIMENTAL
Intervention: Independent risk factors for CCI
Number of subjects: 145
Study 29251709 — intervention group
Group type: EXPERIMENTAL
Intervention: CCI patients
Number of subjects: 145
Study 29251799 — intervention group
Group type: EXPERIMENTAL
Intervention: Atrioventricular junction ablation (AVJA)
Number of subjects: 3358
Study 29251799 — intervention group
Group type: COMPARATOR
Intervention: Rate-slowing drugs
Number of subjects: 3358
Study 29251799 — intervention group
Group type: COMPARATOR
Intervention: Sinus rhythm (SR) patients
Number of subjects: 3358
Study 29251951 — intervention group
Group type: EXPERIMENTAL
Intervention: Socially Disconnected subgroup
Number of subjects: 1571
Study 29251951 — intervention group
Group type: COMPARATOR
Intervention: High Stress/High Contact subgroup
Number of subjects: 1571
Study 29251951 — intervention group
Group type: COMPARATOR
Intervention: Risky Friends and Low Contact subgroup
Number of subjects: 1571
Study 29252124 — intervention group
Group type: EXPERIMENTAL
Intervention: M6620 (ATR inhibitor) + Topotecan (1.25 mg/m²)
Number of subjects: 21
Study 29253081 — intervention group
Group type: EXPERIMENTAL
Intervention: Cohort A: Four cycles of dose-dense doxorubicin and cyclophosphamide, followed by 12 doses of standard paclitaxel plus four cycles of trastuzumab and pertuzumab.
Number of subjects: 397
Study 29253081 — intervention group
Group type: EXPERIMENTAL
Intervention: Cohort B: Four cycles of standard fluorouracil/epirubicin/cyclophosphamide, followed by four cycles of docetaxel with four cycles of trastuzumab and pertuzumab.
Number of subjects: 397
Study 29253081 — intervention group
Group type: EXPERIMENTAL
Intervention: Cohort A: Pertuzumab, trastuzumab, and chemotherapy.
Number of subjects: 397
Study 29253081 — intervention group
Group type: EXPERIMENTAL
Intervention: Cohort B: Pertuzumab, trastuzumab, and chemotherapy.
Number of subjects: 397
Study 29253090 — intervention group
Group type: EXPERIMENTAL
Intervention: HIV-uninfected women in 2011
Number of subjects: 2310
Study 29253090 — intervention group
Group type: EXPERIMENTAL
Intervention: HIV-uninfected women in 2012
Number of subjects: 2310
Study 29253090 — intervention group
Group type: EXPERIMENTAL
Intervention: HIV-infected women
Number of subjects: 2310
Study 29253090 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternal RSV infection
Number of subjects: 2310
Study 29253090 — intervention group
Group type: EXPERIMENTAL
Intervention: Postpartum RSV infection in mothers
Number of subjects: 2310
Study 29253090 — intervention group
Group type: EXPERIMENTAL
Intervention: Infants with RSV illness
Number of subjects: 2310
Study 29253097 — intervention group
Group type: EXPERIMENTAL
Intervention: Dolutegravir (50 mg) plus Lamivudine (300 mg)
Number of subjects: 120
Study 29253846 — intervention group
Group type: EXPERIMENTAL
Intervention: Canagliflozin
Number of subjects: 4401
Study 29253846 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 4401
Study 29253918 — intervention group
Group type: EXPERIMENTAL
Intervention: Motorized spiral colonoscopy (MSC)
Number of subjects: 30
Study 29254220 — intervention group
Group type: EXPERIMENTAL
Intervention: Evaluation of PD-1, PD-L1, and PD-L2 expression in peripheral T-cells
Number of subjects: 0
Study 29254220 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma cytokine levels
Number of subjects: 0
Study 29254376 — intervention group
Group type: EXPERIMENTAL
Intervention: Mirabegron
Number of subjects: 862
Study 29254506 — intervention group
Group type: EXPERIMENTAL
Intervention: High dose interleukin-2 therapy (IL-2)
Number of subjects: 1535
Study 29254506 — intervention group
Group type: COMPARATOR
Intervention: No irAE
Number of subjects: 1535
Study 29254856 — intervention group
Group type: EXPERIMENTAL
Intervention: Single fraction of multi-catheter interstitial high-dose rate brachytherapy (16 Gy)
Number of subjects: 26
Study 29255413 — intervention group
Group type: EXPERIMENTAL
Intervention: Paleolithic diet (PD)
Number of subjects: 0
Study 29255413 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined aerobic and resistance exercise
Number of subjects: 0
Study 29255413 — intervention group
Group type: EXPERIMENTAL
Intervention: Paleolithic diet with combined aerobic and resistance exercise
Number of subjects: 0
Study 29255413 — intervention group
Group type: COMPARATOR
Intervention: Control group (lifestyle ± metformin without intervention)
Number of subjects: 0
Study 29256049 — intervention group
Group type: EXPERIMENTAL
Intervention: OUFCC (urinary free cortisol corrected for creatinine)
Number of subjects: 26
Study 29256908 — intervention group
Group type: EXPERIMENTAL
Intervention: 1-Hz rTMS applied to the right inferior frontal gyrus for 10 days (Monday through Friday for 2 weeks)
Number of subjects: 9
Study 29256908 — intervention group
Group type: EXPERIMENTAL
Intervention: 1-Hz rTMS
Number of subjects: 9
Study 29257710 — intervention group
Group type: EXPERIMENTAL
Intervention: PT2385 at 800 mg twice per day (RP2D)
Number of subjects: 51
Study 29258438 — intervention group
Group type: EXPERIMENTAL
Intervention: Supreme™ laryngeal mask airway (SLMA)
Number of subjects: 584
Study 29258468 — intervention group
Group type: EXPERIMENTAL
Intervention: BD depression
Number of subjects: 88
Study 29258468 — intervention group
Group type: EXPERIMENTAL
Intervention: UP
Number of subjects: 88
Study 29258468 — intervention group
Group type: COMPARATOR
Intervention: mania and mixed states
Number of subjects: 88
Study 29258468 — intervention group
Group type: EXPERIMENTAL
Intervention: Mean activity over 24 hours
Number of subjects: 88
Study 29258468 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-linear variability measures of activity
Number of subjects: 88
Study 29258560 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive therapy (4 hours each weekday for 10 treatment days)
Number of subjects: 3
Study 29258585 — intervention group
Group type: EXPERIMENTAL
Intervention: Endurance training for 26 weeks
Number of subjects: 13
Study 29258618 — intervention group
Group type: EXPERIMENTAL
Intervention: Autologous tumor-derived autophagosome vaccine (DRibbles)
Number of subjects: 4
Study 29258618 — intervention group
Group type: COMPARATOR
Intervention: Docetaxel 75 mg/m²
Number of subjects: 4
Study 29258674 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant chemotherapy plus ipilimumab followed by surgery
Number of subjects: 55
Study 29258674 — intervention group
Group type: COMPARATOR
Intervention: Standard preoperative chemotherapy (platinum doublet regimen) followed by surgery
Number of subjects: 55
Study 29258913 — intervention group
Group type: EXPERIMENTAL
Intervention: Statin therapy
Number of subjects: 14873
Study 29258976 — intervention group
Group type: EXPERIMENTAL
Intervention: Personalized HIV testing recommendation
Number of subjects: 236
Study 29258976 — intervention group
Group type: COMPARATOR
Intervention: Standard HIV testing information
Number of subjects: 236
Study 29258978 — intervention group
Group type: EXPERIMENTAL
Intervention: SMS messages and community BP measurement through task shifting with electronic transfer of measures to the patient and health care team members
Number of subjects: 0
Study 29258978 — intervention group
Group type: EXPERIMENTAL
Intervention: Text messaging intervention
Number of subjects: 0
Study 29259073 — intervention group
Group type: EXPERIMENTAL
Intervention: Panitumumab (6 mg/kg IV every 14 days)
Number of subjects: 9
Study 29259809 — intervention group
Group type: EXPERIMENTAL
Intervention: Tension night splint (TNS) + home exercise programme (HEP)
Number of subjects: 40
Study 29259809 — intervention group
Group type: COMPARATOR
Intervention: Home exercise programme (HEP) only
Number of subjects: 40
Study 29259822 — intervention group
Group type: EXPERIMENTAL
Intervention: PTM202 (bovine colostrum and hyperimmune hen's egg)
Number of subjects: 301
Study 29259822 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 301
Study 29259822 — intervention group
Group type: EXPERIMENTAL
Intervention: PTM202
Number of subjects: 301
Study 29259998 — intervention group
Group type: EXPERIMENTAL
Intervention: High-frequency stimulation of the left prefrontal cortex (PFC)
Number of subjects: 33
Study 29259998 — intervention group
Group type: EXPERIMENTAL
Intervention: High-frequency stimulation of the primary motor cortex (MC)
Number of subjects: 33
Study 29259998 — intervention group
Group type: COMPARATOR
Intervention: Sham stimulation
Number of subjects: 33
Study 29260460 — intervention group
Group type: EXPERIMENTAL
Intervention: Second-line antidiabetic treatment
Number of subjects: 2000
Study 29260603 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Orientation to daily Occupational Performance (CO-OP) Approach, 12 sessions, twice a week, with an additional session for parents' orientation.
Number of subjects: 8
Study 29261402 — intervention group
Group type: EXPERIMENTAL
Intervention: Nasal high flow (NHF) bronchodilator inhalation with salbutamol 2.5 mg/ipratropium bromide 500 μg solution
Number of subjects: 30
Study 29261402 — intervention group
Group type: COMPARATOR
Intervention: Oral bronchodilator inhalation with salbutamol 2.5 mg/ipratropium bromide 500 μg solution
Number of subjects: 30
Study 29261567 — intervention group
Group type: EXPERIMENTAL
Intervention: Partial pressure of arterial carbon dioxide (pCO2)
Number of subjects: 600
Study 29263019 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranolazine (500-1000 mg twice a day)
Number of subjects: 30
Study 29263019 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 29263019 — intervention group
Group type: EXPERIMENTAL
Intervention: Subgroup with improved angina (SAQ-7)
Number of subjects: 30
Study 29263032 — intervention group
Group type: EXPERIMENTAL
Intervention: Plant protein substitution for animal protein
Number of subjects: 0
Study 29263061 — intervention group
Group type: EXPERIMENTAL
Intervention: 300 mg glecaprevir and 120 mg pibrentasvir (single doses) in subjects with chronic kidney disease
Number of subjects: 46
Study 29263061 — intervention group
Group type: EXPERIMENTAL
Intervention: 300 mg glecaprevir and 120 mg pibrentasvir (single doses) under dialysis conditions
Number of subjects: 46
Study 29263061 — intervention group
Group type: EXPERIMENTAL
Intervention: 300 mg glecaprevir and 120 mg pibrentasvir (single doses) under nondialysis conditions
Number of subjects: 46
Study 29263070 — intervention group
Group type: EXPERIMENTAL
Intervention: Alalevonadifloxacin (1,000 mg twice daily for 5 days)
Number of subjects: 30
Study 29263704 — intervention group
Group type: EXPERIMENTAL
Intervention: HIPEC with fast-track recovery strategy
Number of subjects: 9
Study 29263894 — intervention group
Group type: EXPERIMENTAL
Intervention: CART-20 cells (autologous anti-CD20 CAR-modified T cells)
Number of subjects: 0
Study 29263894 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 29264713 — intervention group
Group type: EXPERIMENTAL
Intervention: Dulaglutide 0.75 mg
Number of subjects: 417
Study 29264713 — intervention group
Group type: COMPARATOR
Intervention: Liraglutide 0.9 mg
Number of subjects: 417
Study 29264930 — intervention group
Group type: EXPERIMENTAL
Intervention: Dabigatran
Number of subjects: 0
Study 29264930 — intervention group
Group type: EXPERIMENTAL
Intervention: Apixaban
Number of subjects: 0
Study 29264930 — intervention group
Group type: EXPERIMENTAL
Intervention: Rivaroxaban
Number of subjects: 0
Study 29264930 — intervention group
Group type: EXPERIMENTAL
Intervention: Edoxaban
Number of subjects: 0
Study 29264930 — intervention group
Group type: EXPERIMENTAL
Intervention: Warfarin
Number of subjects: 0
Study 29264930 — intervention group
Group type: COMPARATOR
Intervention: No extended treatment
Number of subjects: 0
Study 29265773 — intervention group
Group type: EXPERIMENTAL
Intervention: LAP-BAND (Apollo Endosurgery Inc.) adjustable gastric banding system
Number of subjects: 652
Study 29265961 — intervention group
Group type: EXPERIMENTAL
Intervention: Neuropsychological assessment using modified standardized assessments, functional assessments, and caregiver/informant reports.
Number of subjects: 0
Study 29265961 — intervention group
Group type: EXPERIMENTAL
Intervention: Adaptive behavior measures, out-of-range developmental assessments, and social-communication measures.
Number of subjects: 0
Study 29265961 — intervention group
Group type: EXPERIMENTAL
Intervention: Recommended framework for neuropsychological evaluation.
Number of subjects: 0
Study 29266363 — intervention group
Group type: EXPERIMENTAL
Intervention: Scaling and root planing (SRP)
Number of subjects: 12
Study 29266856 — intervention group
Group type: EXPERIMENTAL
Intervention: Chikungunya arthritis patients
Number of subjects: 38
Study 29266856 — intervention group
Group type: COMPARATOR
Intervention: Chikungunya virus infection
Number of subjects: 38
Study 29267317 — intervention group
Group type: EXPERIMENTAL
Intervention: CholangioFlex (0.6mm probe)
Number of subjects: 48
Study 29267317 — intervention group
Group type: EXPERIMENTAL
Intervention: AlveoFlex (1.4mm probe)
Number of subjects: 48
Study 29267317 — intervention group
Group type: EXPERIMENTAL
Intervention: Both probes
Number of subjects: 48
Study 29267575 — intervention group
Group type: EXPERIMENTAL
Intervention: XEN45 gel stent implantation
Number of subjects: 15
Study 29267856 — intervention group
Group type: EXPERIMENTAL
Intervention: Pazopanib (PZ)
Number of subjects: 940
Study 29267856 — intervention group
Group type: EXPERIMENTAL
Intervention: Quality-adjusted progression-free survival (QAPFS) with PZ
Number of subjects: 940
Study 29267856 — intervention group
Group type: COMPARATOR
Intervention: Placebo (P)
Number of subjects: 940
Study 29267946 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower cardiovagal tone and baroreflex sensitivity in type 2 diabetes patients
Number of subjects: 206
Study 29267946 — intervention group
Group type: COMPARATOR
Intervention: Control group (glucose-tolerant individuals)
Number of subjects: 206
Study 29267966 — intervention group
Group type: EXPERIMENTAL
Intervention: Copeptin
Number of subjects: 91
Study 29267966 — intervention group
Group type: EXPERIMENTAL
Intervention: AVP
Number of subjects: 91
Study 29267966 — intervention group
Group type: EXPERIMENTAL
Intervention: Copeptin and AVP
Number of subjects: 91
Study 29268712 — intervention group
Group type: EXPERIMENTAL
Intervention: Long time hypertensive group
Number of subjects: 134
Study 29268712 — intervention group
Group type: EXPERIMENTAL
Intervention: Short time hypertensive group
Number of subjects: 134
Study 29268712 — intervention group
Group type: COMPARATOR
Intervention: Healthy control group
Number of subjects: 134
Study 29268720 — intervention group
Group type: EXPERIMENTAL
Intervention: Falls efficacy measured by the Modified Falls Efficacy Scale (MFES)
Number of subjects: 247
Study 29268720 — intervention group
Group type: EXPERIMENTAL
Intervention: Low baseline falls efficacy
Number of subjects: 247
Study 29268720 — intervention group
Group type: EXPERIMENTAL
Intervention: High falls efficacy but poor postural balance
Number of subjects: 247
Study 29268722 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasonography (US) every 6 months
Number of subjects: 0
Study 29268722 — intervention group
Group type: COMPARATOR
Intervention: Non-contrast liver MRI every 12 months
Number of subjects: 0
Study 29268722 — intervention group
Group type: EXPERIMENTAL
Intervention: Dynamic liver CT for confirmation of HCC diagnosis if a focal liver lesion is detected
Number of subjects: 0
Study 29268722 — intervention group
Group type: EXPERIMENTAL
Intervention: Survival of patients who developed HCC within the 3-year follow-up period
Number of subjects: 0
Study 29268739 — intervention group
Group type: EXPERIMENTAL
Intervention: Nasal gene expression profiling
Number of subjects: 53
Study 29268739 — intervention group
Group type: COMPARATOR
Intervention: Bronchial gene expression analysis
Number of subjects: 53
Study 29268751 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-term exposure to ambient particulate matter <2.5 μm (PM2.5)
Number of subjects: 6253
Study 29268751 — intervention group
Group type: COMPARATOR
Intervention: Baseline prevalence of AVC
Number of subjects: 6253
Study 29268751 — intervention group
Group type: COMPARATOR
Intervention: Baseline prevalence of MAC
Number of subjects: 6253
Study 29268751 — intervention group
Group type: COMPARATOR
Intervention: Baseline prevalence of CAC
Number of subjects: 6253
Study 29268758 — intervention group
Group type: EXPERIMENTAL
Intervention: Pamphlet provided by reception staff addressing barriers and enablers to registration, along with an Internet-enabled tablet for registration.
Number of subjects: 6
Study 29268758 — intervention group
Group type: COMPARATOR
Intervention: Control period (no intervention) for 2 weeks before the intervention starts.
Number of subjects: 6
Study 29268807 — intervention group
Group type: EXPERIMENTAL
Intervention: 24-h dietary recalls (EIrecall) in SBS group
Number of subjects: 22
Study 29268807 — intervention group
Group type: EXPERIMENTAL
Intervention: Doubly labelled water method (TEEdlw) in SBS group
Number of subjects: 22
Study 29268807 — intervention group
Group type: COMPARATOR
Intervention: 24-h dietary recalls (EIrecall) in control group
Number of subjects: 22
Study 29268807 — intervention group
Group type: COMPARATOR
Intervention: Doubly labelled water method (TEEdlw) in control group
Number of subjects: 22
Study 29268922 — intervention group
Group type: EXPERIMENTAL
Intervention: iFR (instantaneous wave-free ratio)
Number of subjects: 197
Study 29268922 — intervention group
Group type: COMPARATOR
Intervention: dPR (diastolic pressure ratio)
Number of subjects: 197
Study 29268922 — intervention group
Group type: COMPARATOR
Intervention: dPR (diastolic pressure ratio) during 25% to 75% of diastole
Number of subjects: 197
Study 29268924 — intervention group
Group type: EXPERIMENTAL
Intervention: NT-proBNP
Number of subjects: 1334
Study 29268926 — intervention group
Group type: EXPERIMENTAL
Intervention: Transfemoral THV implantation
Number of subjects: 203
Study 29269252 — intervention group
Group type: EXPERIMENTAL
Intervention: Nestorone®/ethinyl estradiol contraceptive vaginal ring (CVR)
Number of subjects: 905
Study 29269441 — intervention group
Group type: EXPERIMENTAL
Intervention: Microbial dysbiosis presence during exacerbations
Number of subjects: 281
Study 29269441 — intervention group
Group type: EXPERIMENTAL
Intervention: Microbiome composition analysis
Number of subjects: 281
Study 29269559 — intervention group
Group type: EXPERIMENTAL
Intervention: Point-of-care CRP alongside vital signs and objective symptoms measurements
Number of subjects: 5517
Study 29269559 — intervention group
Group type: EXPERIMENTAL
Intervention: Point-of-care CRP
Number of subjects: 5517
Study 29269579 — intervention group
Group type: EXPERIMENTAL
Intervention: Video-assisted mediastinoscopy (VAM) or VAM-lymphadenectomy (VAMLA)
Number of subjects: 105
Study 29269583 — intervention group
Group type: EXPERIMENTAL
Intervention: Endobronchial coil treatment
Number of subjects: 0
Study 29269583 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study 29269796 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous pentamidine at 4 mg/kg (maximum 300 mg)
Number of subjects: 50
Study 29269980 — intervention group
Group type: EXPERIMENTAL
Intervention: Salivary GPX
Number of subjects: 75
Study 29269980 — intervention group
Group type: EXPERIMENTAL
Intervention: Salivary TAC
Number of subjects: 75
Study 29269980 — intervention group
Group type: EXPERIMENTAL
Intervention: Salivary MDA
Number of subjects: 75
Study 29269980 — intervention group
Group type: EXPERIMENTAL
Intervention: Salivary SOD
Number of subjects: 75
Study 29269980 — intervention group
Group type: EXPERIMENTAL
Intervention: Salivary UA
Number of subjects: 75
Study 29269980 — intervention group
Group type: EXPERIMENTAL
Intervention: Salivary 8-OHdG
Number of subjects: 75
Study 29269980 — intervention group
Group type: EXPERIMENTAL
Intervention: Salivary SOD, TAC, GPX, UA
Number of subjects: 75
Study 29270013 — intervention group
Group type: EXPERIMENTAL
Intervention: Asenapine
Number of subjects: 0
Study 29270013 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 29270062 — intervention group
Group type: EXPERIMENTAL
Intervention: Stereotactic ablative radiotherapy (sabr)
Number of subjects: 0